FDA Requires a Vision-Loss Warning on All GLP-1 Drugs, From Ozempic and Zepbound to Foundayo
The short version
- On 9 November 2026 the FDA said it is requiring the makers of all GLP-1 receptor agonist medicines to add the potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy) to the Warnings and Precautions section of their labels.
- NAION is rare. The FDA describes it as acute, painless, decreased vision in one eye, which can include permanent vision loss.
- In the FDA's analysis of 126 randomized trials with 134,253 patients, probable NAION occurred at 6.4 cases per 100,000 person-years on GLP-1 drugs against 3.8 on comparators: 10 cases against 5. Its own real-world study found a higher risk than with DPP-4 inhibitors, but no statistically significant increase against SGLT-2 inhibitors.
- The FDA's list has 12 products, including Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound and Foundayo (orforglipron), approved in 2026. Retatrutide, which is still investigational, is not on it.
- Novo Nordisk said the data "do not establish a cause-and-effect relationship"; Lilly said it is "carefully evaluating the update". The communication is addressed to the holders of approved applications and does not mention compounded or research-labeled products.
The US Food and Drug Administration is requiring the makers of every approved GLP-1 drug to add a warning about a rare eye condition to their labels. In a Drug Safety Communication dated 9 November 2026, the agency said it had found a "potential increased risk" of non-arteritic anterior ischemic optic neuropathy, or NAION, which can cause sudden vision loss in one eye. The action covers semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound) and the newest drug in the class, orforglipron (Foundayo). Here is what the FDA found, which drugs are covered, what it tells patients and prescribers, and what it leaves out, as of 12 November 2026.
The action in brief
| Question | Answer, from the FDA |
|---|---|
| What did the FDA announce? | A "potential increased risk" of NAION in patients taking GLP-1 receptor agonists, and a required change to the labels of every one of them |
| Who has to act? | "Application holders for all GLP-1 RA medications", who must add information about the risk to the Warnings and Precautions section of labeling |
| What is NAION? | "A rare condition that can result in acute, painless, decreased vision in one eye, including permanent vision loss" |
| What causes it? | Decreased blood flow to the front part of the optic nerve, the optic disc; "the underlying cause is not completely understood" |
| Do the drugs cause it? | The FDA's conclusion is "a potential increased risk of rare NAION events". Its review of animal data "did not identify a mechanism". CNBC reported that a causal relationship has not been established |
| What started the review? | A study published in July 2024 in JAMA Ophthalmology on NAION in patients prescribed semaglutide. The FDA "identified several limitations" in it but decided further assessment was warranted |
Source: FDA Drug Safety Communication, 9 November 2026, read on 12 November 2026.
Which drugs are covered
The FDA's table lists 12 approved GLP-1 receptor agonists. Tirzepatide, it notes, acts on both the GIP and the GLP-1 receptor.
| Brand | Active ingredient | FDA approval year |
|---|---|---|
| Byetta | exenatide | 2005 |
| Victoza | liraglutide | 2010 |
| Trulicity | dulaglutide | 2014 |
| Saxenda | liraglutide | 2014 |
| Xultophy | liraglutide with insulin degludec | 2016 |
| Soliqua | lixisenatide with insulin glargine | 2016 |
| Ozempic | semaglutide | 2017 |
| Rybelsus | semaglutide | 2019 |
| Wegovy | semaglutide | 2021 |
| Mounjaro | tirzepatide | 2022 |
| Zepbound | tirzepatide | 2023 |
| Foundayo | orforglipron | 2026 |
Source: FDA Drug Safety Communication, table of FDA-approved GLP-1 RAs. The FDA notes that the Byetta application was voluntarily withdrawn in 2025 "(not for reasons of safety or effectiveness)" because it was no longer marketed, and that only generic exenatide is marketed now.
Retatrutide, Lilly's investigational drug, is not on the list, because it is not approved. On a separate page the FDA says retatrutide "cannot be used in compounding under federal law". For what its trials have reported, see retatrutide side effects by dose; for the newest approved drug, our orforglipron (Foundayo) guide.
What the numbers show
Reports of NAION to the FDA's adverse event system were "challenging to interpret", the agency said, because the risk factors for NAION often overlap with conditions common in people who take these drugs. So it ran its own analyses and reviewed the published studies.
| Evidence | What the FDA found |
|---|---|
| Pooled analysis of 126 randomized controlled trials: 134,253 patients, 288,879 person-years of exposure | 15 probable NAION cases: 10 in patients on a GLP-1 drug, 5 on placebo, none on other glucose-lowering drugs. That is 6.4 cases per 100,000 person-years on GLP-1 drugs against 3.8 on comparators |
| FDA Sentinel study (Commercial Network) of adults with type 2 diabetes who started a GLP-1 drug, an SGLT-2 inhibitor or a DPP-4 inhibitor between 2019 and 2024 | 26 to 32 cases per 100,000 person-years in every group (GLP-1 drugs 30 to 32, SGLT-2 inhibitors 31, DPP-4 inhibitors 26). Against DPP-4 inhibitors the risk was higher (hazard ratio 1.43, 95% CI 1.02 to 2.01). Against SGLT-2 inhibitors there was no statistically significant increase (hazard ratio 1.19, 95% CI 0.91 to 1.54) |
| Published observational studies | "Methodologically rigorous studies consistently reported an increased risk" in people with type 2 diabetes starting a GLP-1 drug, compared with those starting a DPP-4 or SGLT-2 inhibitor |
| Animal data | No mechanism identified |
| Case reports | NAION cases "have been reported for all currently marketed GLP-1 RA products" |
Source: FDA Drug Safety Communication, 9 November 2026.
The trial counts are small: 15 probable cases in 288,879 person-years, and the two rates differ by 2.6 cases per 100,000 person-years. The real-world rates are higher in every group, including people not taking a GLP-1 drug; that study covered only adults with type 2 diabetes, and the FDA lists diabetes among the risk factors for NAION. For comparison, the FDA cites published estimates of 2.3 to 10.2 cases per 100,000 people a year in adults older than 50.
Risk factors and symptoms
The FDA lists smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease as possible risk factors. If NAION has occurred in one eye, the risk that it occurs in the other eye is higher, and patients with a history of NAION are at increased risk of it coming back.
The symptoms it lists:
- sudden, painless vision loss in one eye, which may be noticed on waking
- blurred or missing parts of vision, such as blind spots or tunnel vision
- distortion of colors
- reduced central sharpness, such as blurry or hazy spots
What the FDA tells patients and prescribers
Patients. Contact a health care professional "right away" with any of these symptoms. After a NAION event, talk with a health care professional "about whether to continue taking their GLP-1 RA medication or to stop it". The communication does not tell people without symptoms to stop treatment.
Prescribers. Tell patients to report sudden vision changes in one eye at once. "If NAION is suspected, promptly refer the patient to an ophthalmologist for evaluation." And "consider discontinuing the GLP-1 RA in patients who develop NAION, unless the benefits of treatment clearly outweigh the risk."
What the drugmakers said
Novo Nordisk, which makes Ozempic and Wegovy, said it "continues to believe the data do not establish a cause-and-effect relationship, and we remain confident in the benefit-risk profile of our GLP-1 medicines", CNBC reported. Eli Lilly, which makes Mounjaro, Zepbound and Foundayo, said it is "carefully evaluating the update and will respond to FDA promptly." The FDA's communication gives no date for the new labels.
Europe acted first, on semaglutide only
The European Medicines Agency's safety committee, PRAC, concluded in June 2025 that NAION is a "very rare" side effect of semaglutide medicines, meaning it may affect up to 1 in 10,000 people, and recommended adding it to the product information of the semaglutide medicines it named: Ozempic, Rybelsus and Wegovy. "If NAION is confirmed, treatment with semaglutide should be stopped," it said. CNBC reported that the UK medicines regulator later issued a similar warning, and that both the European and the British warnings focused on semaglutide. The FDA's covers the whole class.
Compounded and research-labeled GLP-1s
The labeling change is addressed to the companies holding approved applications, and the communication does not mention compounded drugs or products sold for research. On its page about unapproved GLP-1 drugs, the FDA says "compounded drugs are not FDA approved", which means the agency "does not review compounded drugs for safety, effectiveness or quality before they are marketed." The same page says the FDA has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide "that are falsely labeled 'for research purposes' or 'not for human consumption.'"
The FDA words its conclusion as a risk "in patients taking GLP-1 RAs", drawn from clinical trials and real-world data on GLP-1 drugs. Our guides to compounded semaglutide and semaglutide side effects carry the wider background.
What to watch
- The new labels. Each drug's Warnings and Precautions section is to carry the NAION information. The communication gives no date.
- Lilly's response, which it said would come "promptly".
- Action on unapproved GLP-1 sellers, which we log in the enforcement tracker.
This page is news on an FDA document, not medical advice. The drugs listed are prescription medicines; whether one suits a person, and what to do about a change in vision, is a matter for a licensed health professional. Peptide Bureau covers research peptides for laboratory research use only.
Questions readers ask
Does Ozempic cause vision loss?
On 9 November 2026 the FDA said there is a potential increased risk of NAION, a rare condition that can cause sudden, painless vision loss in one eye, in patients taking GLP-1 drugs, semaglutide (Ozempic, Wegovy, Rybelsus) included. It is requiring a warning on every GLP-1 drug's label. Novo Nordisk says the data do not establish cause and effect.
What is NAION?
Non-arteritic anterior ischemic optic neuropathy. The FDA describes it as a rare condition that can cause acute, painless, decreased vision in one eye, including permanent vision loss. It comes from decreased blood flow to the front of the optic nerve; the underlying cause is not completely understood.
How common is NAION with GLP-1 drugs?
In the FDA's analysis of 126 trials, 6.4 cases per 100,000 person-years on GLP-1 drugs against 3.8 on comparators, from 15 cases in total. In the FDA's real-world study of adults with type 2 diabetes, rates ran from 26 to 32 per 100,000 person-years across all the drug groups compared. Europe's medicines agency classes it as very rare with semaglutide: up to 1 in 10,000 people.
Which GLP-1 drugs need the new warning?
All FDA-approved GLP-1 receptor agonists. The FDA's list: Byetta (exenatide), Victoza, Saxenda and Xultophy (liraglutide), Trulicity (dulaglutide), Soliqua (lixisenatide), Ozempic, Rybelsus and Wegovy (semaglutide), Mounjaro and Zepbound (tirzepatide) and Foundayo (orforglipron). Byetta itself is no longer marketed; generic exenatide is.
What does the FDA say to do about vision changes on a GLP-1?
Contact a health care professional right away about sudden, painless vision loss in one eye, blind spots or tunnel vision, distorted colors or blurry spots. After a NAION event, the FDA says to talk with a health care professional about whether to continue the medicine or stop it.
Does the warning cover compounded semaglutide or retatrutide?
The labeling change is for the makers of approved products, and the communication does not mention compounded or research-labeled products. The FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness or quality before they are marketed. Retatrutide is investigational and is not on the FDA's list.
Sources
- FDA Drug Safety Communication: FDA requires safety labeling changes for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) due to potential increased risk of rare but serious eye condition, 9 November 2026; read 12 November 2026
- CNBC: FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound (Elsa Ohlen), 10 November 2026
- European Medicines Agency: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 June 2025, 6 June 2025; read 12 November 2026
- FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss, content current as of 1 October 2026; read 12 November 2026
- Hathaway JT et al.: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide, JAMA Ophthalmology 2024;142(8):732-739 (the study the FDA cites), July 2024